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Dimethyl sulphoxide and methylsulfonylmethane are two related nutritional supplements used for symptomatic relief of
osteoarthritis (OA). We conducted a meta-analysis to evaluate their eﬃcacy in reducing pain associated with OA. Randomized or
quasi-randomized controlled trials (RCTs), identiﬁed by systematic electronic searches, citation tracking and searches of clinical
trial registries, assessing these supplements in osteoarthritis of any joint were considered for inclusion. Meta-analysis, based on
diﬀerence in mean pain related outcomes between treatment and comparator groups, was carried out based on a random eﬀect
model. Seven potential trials were identiﬁed of which three RCTs, two DMSO and one MSM (total N = 326 patients) were
eligible for inclusion. All three trials were considered high methodological quality. A signiﬁcant degree of heterogeneity (χ2 = 6.28,
P = .043) was revealed. Two studies demonstrated statistically signiﬁcant (but not clinically relevant) reduction in pain compared
with controls; with one showing no group diﬀerence. The meta-analysis conﬁrmed a non signiﬁcant reduction of pain on visual
analogue scale of 6.34 mm (SE = 3.49, 95% CI, −0.49, 13.17). The overall eﬀect size of 1.82 was neither statistically nor clinically
signiﬁcant. Current evidence suggests DMSO and MSM are not clinically eﬀective in the reduction of pain in the treatment of
OA. No deﬁnitive conclusions can currently be drawn from the data due to the mixed ﬁndings and the use of inadequate dosing
periods.
1.Introduction
Osteoarthritis(OA)isthemostcommonofalljointdisorders
and aﬀects over 30 million people in the US and 1 in
10 people aged 35–75 in the UK [1] and is associated
with pain and functional disability, which in turn leads
to reduced quality of life and increased risk of further
morbidity and mortality [2]. The treatment of OA is largely
symptomatic and includes analgesics, NSAIDs as well as
exercise and surgical intervention [3]. The long-term use
of NSAIDs is associated with serious gastrointestinal side
eﬀects [4, 5] including 12000 hospital admissions and
∼2000 deaths in the UK every year [6]. Patients with OA
turn to complementary and alternative medicine (CAM) to
gain symptomatic relief and avoid iatrogenic illness with OA
being the sixth most common condition treated with CAM
[7]; OA patients use of CAM is substantially greater that in
the general population with a reported prevalence of up to
90% [8, 9].
Two nutritional supplements, dimethyl sulfoxide
(DMSO, an organic form of sulfur commercially prepared
from lignin) and its oxidized form, methylsulfonylmethane
(MSM, occurring in green plants fruits and vegetables)
have been used to treat arthritic conditions [10]. DMSO
is converted in the body to MSM and as MSM remains
in the body for longer than DMSO [11], it is suggested
that many of the beneﬁcial eﬀects of DMSO are due to the
long lasting fraction of DMSO which is converted to MSM
[12]. Both have similar pharmacological properties and
their putative eﬀects and mechanisms have been reviewed
previously (MSM [13–15]; DMSO [16–19]; both [20, 21]).
MSM and DMSO have been reported to reduce peripheral
pain [22–24], inﬂammation [25] and arthritis [26], and
mightinhibitthedegenerativechangesoccurringinOA[27].2 Evidence-Based Complementary and Alternative Medicine
These compounds may act through their ability to stabilize
cell membranes, slow or stop leakage from injured cells and
scavenge hydroxyl free radicals which trigger inﬂammation
[23, 25, 28–33]. Their sulfur content may also rectify dietary
deﬁciencies of sulfur improving cartilage formation [34, 35].
DMSO is a topical agent, diluted for therapeutic use
(concentrations are expressed %(v/v)). It penetrates the skin
and it is also used as a carrier to aid penetration of other
medications [24, 28, 36]. Clinicians are advised to prescribe
DMSO for OA for at least three months to ensure a clinical
eﬀect. However the optimum dosage for this supplement in
OA has not been clearly evaluated as no dose ranging studies
have been conducted. Previous empirical reports suggest
that the therapeutic concentrations of DMSO are 60%–90%
[18, 37] and that doses under 10% are probably clinically
inactive [37–39]. There is limited formal safety data and no
long-term assessment of DMSO although the toxicity of oral
DMSO appears very low (LD50 = 14.5g/kg body weight).
Adverse eﬀectsassociatedwithtopicalDMSOadministration
have been reported (GI upset, skin irritation, and garlic like
taste, breath and body odour) [40, 41]. Its garlic odour can
compromise blinding in double blinded trials.
MSM is used orally and topically. Like DMSO, the
treatment duration for OA is at least three months. The
optimum dosage has not been clearly deﬁned as no dose
ranging studies have been carried out. The suggested oral
therapeutic doses is 4–6g per day [42, 43], although doses
of up to 20g/day have also been used [44]; over the counter
preparations are typically 1–5g daily [45]. There is limited
formal safety data and no long term assessment. However,
MSM is rapidly excreted from the body [46, 47]a n d
animal toxicity studies of MSM showed only minor adverse
events using doses of 1.5g/kg and 2.0g/kg of MSM for 90
days. This dose represents a human dose of 105–140g/day,
which is equivalent to 17–23 times the proposed maximum
recommended human dose of 6g/day [48]. A further study
conﬁrmed MSM had no toxic eﬀects on either pregnant rats
ortheirfoetus[49].Onlyminoradverseeﬀectsareassociated
with MSM administration in humans and include allergy, GI
upsets and skin rashes [50].
Two systematic reviews have also been conducted on
these supplements. Ameye and Chee [13]c o n d u c t e da
systematic review of a range neutriceuticals in OA which
included MSM and concluded that MSM showed “mod-
erate” evidence of eﬃcacy. Brien et al. [21] reported that
current evidence precludes deﬁnitive conclusions about the
eﬃcacy of either supplement but recommended further
investigation addressing methodological concerns including
optimal dosage and treatment duration. A meta-analysis
to assess the most precise estimate of the eﬃcacy of these
supplementsisthereforetimelygiventheirfrequentuse[8,9]
and pertinent because of the withdrawal of some COX-2
inhibitors [5].
2. Methods
2.1. Literature Search Strategy. Searches were performed
using the following electronic databases to identify relevant
Table 1: Search strategy for DMSO.
(1) Explode “osteoarthritis”/all subheadings
(2) Explode “degenerative arthritis”/all subheadings
(3) Osteoarthr$
(4) (1)–(3)
(5) Dimethyl sulfoxide
(6) DMSO
(7) (5)–(6)
(8) Clinical trial
(9) Double blind
(10) Single blind
(11) RCT
(12) Placebo
(13) Randomised
(14) Comparative study
(15) Evaluation study
(16) Control
(17) 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15
(18) 4 AND 7 AND 17
(19) LIMIT 18 to HUMAN
studiesavailableforinclusioninthemeta-analysis;Cochrane
Library (1970–2008), MEDLINE (1950–2008), EMBASE
(1980–2008), AMED (1985–2008), CINAHL (1982–
2008), SCOPUS (1996–2008) and the National Library
for Health (Complementary and Alternative Medicine
Specialist Library). Free text searches were performed on
each database with the following keywords: osteoarthritis,
degenerative joint disorder, dimethyl sulfoxide, DMSO,
methylsulfonylmethane, MSM, clinical trial: double blind;
single blind; RCT; placebo; randomized; comparative study;
evaluation study; control. The search strategies for dimethyl
sulfoxide and methylsulfonylmethane are shown in Tables 1
and 2,r e s p e c t i v e l y .
Citation tracking was undertaken to identify unpub-
lished trials. As numerous pharmaceutical companies mar-
ket DMSO, it was impractical to contact each of them
for unpublished data. Finally we additionally searched
four clinical trials registries (http://www.clinicaltrials.gov/;
http://www.controlled-trials.com/; http://www.actr.org.au/;
and http://www.umin.ac.jp/ctr/), to identify ongoing trials.
The last update of searches was performed in June 2008.
2.2. Trial Selection. All articles that reported randomized
or quasi-randomized controlled trials (RCTs) comparing
oral or topical formulations of DMSO or MSM in the
treatment of OA were identiﬁed. As current data shows that
using greater than 10% DMSO [35–37]a n do v e r1 g / d a y
MSM [45] are needed for therapeutic eﬀects only RCTs
assessing at least these minimal levels were included. RCTs
were included if they were; in humans; reported comparison
of DMSO or MSM to placebo; used validated outcome
measures for OA; and did not include patients with other
joint pathology.Evidence-Based Complementary and Alternative Medicine 3
Table 2: Search strategy for MSM.
(1) Explode “osteoarthritis”/all subheadings
(2) Explode “degenerative arthritis”/all subheadings
(3) Osteoarthr$
(4) (1)–(3)
(5) Methylsulfonylmethane
(6) MSM
(7) (5)–(6)
(8) Clinical trial
(9) Double blind
(10) Single blind
(11) RCT
(12) Placebo
(13) Randomised
(14) Comparative study
(15) Evaluation study
(16) Control
(17) 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15
(18) 4 AND 7 AND 17
(19) LIMIT 18 to HUMAN
2.3. Data Extraction. Data was extracted independently by
two of the authors (S.B. and P.P.). Data regarding publi-
cation status, trial design, patient characteristics, treatment
regimens, outcome measures, results and ﬁndings were
extracted. Eﬀect sizes were calculated where appropriate.
Where information was insuﬃcient the authors were con-
tacted to request missing information. Disagreements were
resolved by discussion by all three reviewers and subsequent
consensus.
2.4. Quality Assessment. Two reviewers (S.B. and P.P.) inde-
pendently assessed the trial quality using the JADAD [51]
scale to assess randomization, blinding and withdrawal. The
total JADAD score is 5 and studies were considered low
quality if they reported a score less than 3, or high quality for
scores3–5.Additionalqualityassessmentwasalsoconducted
includingassessmentofconcealmentoftreatmentallocation.
Assessment of internal and external validity for these papers
have also been reported elsewhere [21]. Disagreements were
resolved by discussion with the third author.
2.5. Data Synthesis. The selected outcome measure for
analysis was the measurement of pain, as this is the most
patient relevant outcome in this condition. The primary
o u t c o m em e a s u r ew a sm e a nc h a n g ei np a i nf r o mb a s e l i n e .
Pain levels were assessed using either a 100mm visual ana-
logues scales (VAS) and on the Western Ontario MacMaster
Osteoarthritis Index (WOMAC) pain subscale [52]. As the
WOMAC subscales have a 0–20 score, these are adjusted
up to a 0–100 range for comparability. These were used
to assess the diﬀerences between the intervention groups
(MSM or DMSO) and the control groups (placebo or
standard conventional treatment, diclofenac). Data points
were chosen at the end of the treatment period.
2.6. Statistical Analysis. Summary estimates of the treatment
eﬀectwere calculatedusing the weighted means of the within
study treatment eﬀects [53]. Weighted mean diﬀerences
and 95% conﬁdence intervals (CI) were calculated using
both a ﬁxed and random eﬀects model. Where data were
insuﬃcient the original authors were contacted to request
the missing information. Sensitivity analyses were conducted
where appropriate. Eﬀect sizes were calculated by dividing
the diﬀerence in the changes, from baseline to the end of
the trial period, between treatment groups by the estimated
standard error. An eﬀect size of about 0.8 is considered
minimally clinically relevant [54]. Chi square test was used
to investigate the heterogeneity in the treatment diﬀerence
parameter across the studies. Publication bias was explored
by using a funnel plot, whereby eﬀect estimates of the pain
were plotted against trial sample size. The funnel plot was
examined visually but due to the small number of studies it
was not feasible to statistically test for symmetry.
3. Results
3.1. Three RCTs Met Inclusion Criteria. A total of seven
citations were retrieved from the databases that met the
inclusion criteria [36, 42, 43, 55–58]. Two further clinical
trials were identiﬁed from citation tracking [39, 59]. No fur-
ther studies were identiﬁed from searching clinical trials reg-
istries. Citations were excluded if: they were not randomized
placebo controlled trials; they reported an intervention other
than DMSO/MSM; assessed another treatment condition; or
they did not assess either DMSO or MSM.
Seven double blind, placebo controlled, randomized
trials, assessing either DMSO or MSM in the treatment of
OA in our literature search which met the inclusion criteria
were identiﬁed for possible inclusion [36, 39, 42, 43, 56,
57, 59]. Of these, three were eligible for inclusion in the
meta-analysis. Four trials were excluded because either (i)
DMSO was not speciﬁcally assessed as a therapeutic agent
[57, 59]; (ii) there was incomplete data [42] (mean and
SD for placebo group were not reported in the text and
attempts to contact the authors were unsuccessful); or (iii)
the pain scale was assessed using a Likert scale rather than
VAS [39] and hence continuous data could not be extracted
for the analysis. Only selected data from one study [36]w e r e
included; this study had three intervention arms (diclofenac
versusDMSOversusplacebo)soonlythearmsrelatingtothe
assessment of DMSO versus placebo were included. A search
oftrialregistriesyieldednoongoingtrials.Thereforetheﬁnal
analysis included three studies, one of which assessed MSM
[43]a n dt w oD M S O[ 36, 56].
3.2. Description of Studies. Table 3 describes the main study
characteristics of the studies included in the meta-analysis.
Further study details relating to the studies included in
this meta-analysis can be obtained from our recent review
of all clinical trials assessing DMSO/MSM in OA [21].
Overall,thetrialsallocated326patientsofwhich161received
active treatment (DMSO, N = 136 or MSM, N = 25).
All three trials assessed patients with OA of the knee4 Evidence-Based Complementary and Alternative Medicine
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joint. Two trials assessed the supplement DMSO topically
administered [36, 56] and one MSM, oral administration
[43]. All trials assessed these supplements as an alternative
rather than adjunctive treatment for OA of the knee, and
rescue medication was allowed. The average mean age of the
patients included in these trials ranged from 56 [43]t o6 2
years [36, 56].
3.2.1. Baseline Characteristics. Baseline demographic char-
acteristics were reported in all studies and all showed no
signiﬁcant diﬀerences between groups. However, the data
describing the characteristics of the patients entered into
these three trials was not fully reported by the trials. The
average duration of OA was reported in only the Kim study
(mean duration of arthritis was 6 years); although patients
were included in the Bookman and Eberhardt studies only
if they had radiological diagnosed OA for a minimum of
6 months or 5 years, respectively. The severity of OA of
included patients was reported in only one trial [43]w h i c h
stated 95% of patients entered had low to moderate OA (i.e.,
Kellegren-Lawrence grades between 0 and 2).
3.2.2.StudyMedication. Allstudiesassessedthesupplements
as alternative treatments with all concurrent systemic and
topical medications stopped prior to commencement of the
study. The use of rescue medication was reported in two of
the studies [36, 43] .T h ed o s a g ea n dt r e a t m e n td u r a t i o no f
the supplements in these trials has been previously reviewed
and highlighted concerns about inadequate treatment dura-
tion and dosage of these supplements assessed in clinical
trials [21]. The doses employed by all three trials assessed in
this meta-analysis were all below current recommendations.
Duration of treatment was also inadequate in two (the
DMSO trials [36, 56]) of the three trials; the Kim trial
assessed MSM for an adequate duration. Compliance assess-
ment was reported in two of the studies ([43] pill count; [36]
weighing medication bottles). No follow up assessment was
performed in any of the three trials.
3.2.3. Pain as the Primary Outcome. Pain was assessed as the
primary eﬃcacy outcome in all these trials. Pain was assessed
either by 0–100mm VAS [56] or the WOMAC pain subscale
[36, 43]. Those studies reporting pain via the WOMAC pain
scales either assessed this using or 0–100 scale [43] or a 0–20
scales [36]; the latter results were scaled up to a 0–100 range
for comparability.
The Eberhardt study [56], although it included more
patients than the other studies, did not provide any a
priori power calculations. However, the observed diﬀerence
between treatment groups in reduction of pain from baseline
to end of treatment of 11.7mm was shown to be statistically
signiﬁcant, P = .0019; and our sensitivity analysis conﬁrmed
power was adequate, that is, greater than 90%. Bookman
et al. [36] calculated that 50 patients per group, including
allowing for dropouts, would be required for an 80% power
to detect a speciﬁed diﬀerence between the two treatment
arms and a previous analysis conﬁrmed power was adequate
[21]. Kim et al. [43] included a power calculation for the
improvement from baseline to 12 weeks, claiming that 25
patients per group would be suﬃcient to detect with 80%
power an improvement in pain score of 25%; however this
was not based on the diﬀerence between treatment groups.
Our subsequent sensitivity analysis conﬁrmed this study had
a power of 55% to detect a diﬀerence between treatment
groups at 5% level of signiﬁcance.
3.2.4. Trial Quality Was High. Table 4 reports the method-
ological quality characteristics of the included trials. All
three trials were of high quality, scoring JADAD scores of
either 4 [56]o r5[ 36, 43]. All trials were reported as
being randomized. The allocation sequence was reported
as being adequately generated in two of the trials [36,
43] but no details were provided in the Eberhardt study
regarding the randomization process [56]. All the trials
were adequately double blinded with the reported use of
identical dummy tablets (MSM) or dummy gel (DMSO).
They all described withdrawals and exclusions and analyzed
all randomly assigned patients and hence conducted an
intention to treat. Two of the trials [36, 56] reported their
approach for handling missing data; using last observation
carried forward for imputations [60].
3.2.5. Meta-Analysis—Eﬀect on Joint Pain. Key data from the
included trials is presented in Table 5. Two of the trials [43,
56]r e p o rt e dm e a nd i ﬀerences that favour DMSO/MSM over
placebo with eﬀect sizes of 3.53 and 2.06, respectively; and
both trials show 95% CI that do not overlap zero indicating
signiﬁcant diﬀerences. Bookman et al. [36] identiﬁed no
group diﬀerences in pain reduction (eﬀect size = 0.0). The
initial ﬁxed eﬀects meta-analysis of all the trials indicates a
statistically signiﬁcant reduction of pain scores of 6.3mm
(CI: 2.41, 10.27) from baseline in favour of DMSO/MSM
compared to placebo (Figure 1). However this change is
not clinically signiﬁcant; a signiﬁcant improvement of 9–
12mmonWOMACsubscalesinpain,isconsideredclinically
relevant [61–63]a si sa>17.5mm change [64] in VAS pain
scales.
A chi-squared test of homogeneity was just signiﬁcant
(χ2 = 6.28, P = .043), suggesting that the eﬀects are more
variable than would be expected by chance and indicating
inconsistencies in the results of the studies. A random eﬀects
meta-analysis identiﬁed a slight increase in SE of the mean
diﬀerence of 6.3mm with SE = 3.49S and 95% CI, (−0.49 to
13.17) which is not quite statistically signiﬁcant. The funnel
plot also conﬁrmed asymmetry in the results, due to the
Bookman et al. study [36] to the left of the common eﬀect
indicating the possibility of publication bias.
4. Discussion
Theﬁndingsofthismeta-analysissuggestthatbasedonavail-
able evidence, DMSO/MSM leads to an overall reduction
in pain VAS of 6.34mm compared to placebo. This is not
statistically signiﬁcantly superior to placebo in reducing pain
associated with OA of the knee. Results from the Bookman
trial [36] showed no diﬀerence in eﬀect between treatmentEvidence-Based Complementary and Alternative Medicine 7
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Figure 1: Meta-analyses of randomized controlled trials.
and placebo which is in contrast to the results from the
other two trials; this may be due to a larger than anticipated
placebo response or may reﬂect possible publication bias.
Clinical signiﬁcance is critical for meaningful meta-
analyses [65] designed to assist clinicians in their decision
making. Current guidelines suggest a minimal clinically
important improvement (MCII) for the pain subscale for
WOMAC in patients with knee OA requires a minimum
change of 19.9mm from baseline to end of treatment [61];
whilst the MCII for VAS of pain in this condition is a
minimum of 17.5mm [64]. It has also been observed that
baseline pain levels aﬀect patient perceived clinical signif-
icance. Recommendations have been proposed for future
trials that are based on reporting MCII speciﬁc to baseline
severity levels [61]. Pain score reductions from baseline to
end of treatment, in those receiving active treatment with
DMSO were 12.5mm ([36]; WOMAC pain subscale) and
42.7mm ([56]; VAS); and 14.6mm ([43]; WOMAC pain
subscale) for patients receiving MSM. Based on current
guidelines, only those patients in the Eberhardt study (both
active and placebo treated) reported clinically meaningful
reductions in their pain and showed a reduction in pain
levelscomparablewithstandardconventionaltreatmentwith
COX 2 inhibitors such as Rofecoxib (35.4mm decrease [66];
28.1mm [67]). This meta-analyses conﬁrms that based on
the current limited evidence these nutritional supplements
are neither statistically nor clinically more eﬀective than
placebo in reducing pain in knee OA.
4.1. Strengths and Limitations. Only randomized, double
blind, placebo controlled trials were included in this inves-
tigation. Our review is based on a systematic and thorough
literature search. It is unlikely we missed relevant trials data
but as possible data was not sought from pharmaceutical
companies this cannot be ruled out. Data extraction, includ-
ing quality assessment, was completed independently by two
authors to minimize bias. The reporting quality of the trials
was acceptable and the quality assessment tool is validated
and its components are associated with bias. All three studies
assessed OA of the knee hence enabling direct comparison
between trials.
There are some limitations of this meta-analysis. First,
only three trials were available for inclusion assessing N =
326 patients in total, of which N = 161 received active treat-
ment. Further trials may therefore aﬀect the future assess-
mentofthesesupplements.Inaddition speciﬁcmethodolog-
ical concerns have been identiﬁed in these trials including
the issue of adequate treatment period with only one study
assessing the supplements for a clinically relevant time [43].
4.2. Implications for Research and Clinical Practice. Recent
reviews ([21] DMSO and MSM; [13] MSM)) of these
supplements for OA suggest further studies of these nutri-
tional supplements may be warranted if the study design
takes into account the methodological issues identiﬁed in
this article. This meta-analysis does not currently provide
robust evidence to support the use of DMSO or MSM for
OA however the conclusions are aﬀected by the number
and quality of included trials. The three trials assessed
had good methodological quality and adequate reporting
yet signiﬁcant methodological concerns about dosing and
treatment duration temper any deﬁnitive conclusions. In
addition, due to the paucity of studies of these supplements,
the publication of further trials may have a major eﬀect on
these recommendations.
If we wish to further evaluate these supplements then
large scale trials are needed that are adequately powered and
assesspatientsforaclinicallyrelevantdurationusingoptimal
dosage.Futuretrialsshouldalsoreporttheminimalclinically
important improvement with reference to the patient’s
baseline severity [61]. A search of clinical trial registries
revealed no ongoing trials and it seems unlikely that suitable
evidence investigating the eﬀectiveness of these supplements
will become available in the near future. The implications for
current clinical practice are that these supplements are not
speciﬁcally eﬀective in decreasing the pain associated with
OA knee. Given the additional lack of safety reporting data
as previously described in a recent systematic review [21], it
is also not possible to have clarity about their safety.
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